Your session is about to expire
← Back to Search
Virus Therapy
Fluad vaccine for Influenza
Phase 4
Waitlist Available
Led By Richard B Kennedy
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 8, day 28
Awards & highlights
Study Summary
This trial is investigating why the elderly have a weaker immune response to flu vaccines, with the hope of developing more effective vaccines in the future.
Eligible Conditions
- Influenza
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Hemagglutination Inhibition Ab Titer
Innate Cell IFNa2a Production
Innate Cell miRNA Expression
+4 moreSecondary outcome measures
CD4/CD8 Ratio
CMV Serostatus
Innate Cell Phenotype
+2 moreTrial Design
2Treatment groups
Active Control
Group I: Fluad vaccineActive Control1 Intervention
Subjects receive a single dose of the Fluad influenza vaccine.
Group II: Fluzone vaccineActive Control1 Intervention
Subjects receive a single dose of the Fluzone High-Dose influenza vaccine.
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,209 Previous Clinical Trials
3,766,893 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,269 Previous Clinical Trials
5,481,228 Total Patients Enrolled
Richard B KennedyPrincipal InvestigatorMayo Clinic
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger